Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP)

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Gómez Almaguer, David ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Alemtuzumab; ITP; Monoclonal antibodies; Purpura; Rituximab

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VELTUZUMAB;

ANAPHYLAXIS; AUTOIMMUNE DISEASE; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SPLENECTOMY; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84859745901     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155213     Document Type: Review

References (12)

1. Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hem Oncol Clin North Am. 2009;23:1213-21.
2. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-86.
3. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates tan dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755-62.
4. Li Z, Mou W, Lu G, Cao J, He X, Pan X, et al. Low dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93:91-8.
5. Dierickx D, Delannoy D, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol. 2011;86:278-91.
6. Lim, SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993;84:542-4.
7. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAB for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009;11:200-7.
8. Gómez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116:4783-5.
9. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25-33.
10. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999-1004.
11. Zaja F, Battista ML, Pirrota MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930-3.
12. Marsh JC, Gordon-Smith EC. CAMPATH 1H in the treatment of autoimmune cytopenias. Cytotherapy. 2011;3:189-95.